SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: John McCarthy who wrote (9914)1/3/2004 7:28:19 PM
From: Ian@SI  Read Replies (1) | Respond to of 52153
 
Barron's takes a gentle shot at AZN...

online.wsj.com

MONDAY, JANUARY 5, 2004

Heartburn Hotel
The purple-pill maker has been flying, but keep one eye on the questions about its new drugs

By BILL ALPERT

INVESTORS LIKE ASTRAZENECA, with good reason. Since emerging from the 1999 combination of Sweden's Astra and Britain's Zeneca, the company has tapped a pipeline of successful drugs -- such as Nexium, its widely advertised "purple pill" for heartburn.
[snip]